CSIMarket Company Name, Ticker, Industry, else..
 
Bioatla Inc   (NASDAQ: BCAB)
Other Ticker:  
 
 
Price: $0.8238 $-0.02 -2.854%
Day's High: $0.8834 Week Perf: 4.04 %
Day's Low: $ 0.81 30 Day Perf: 27.9 %
Volume (M): 588 52 Wk High: $ 1.72
Volume (M$): $ 485 52 Wk Avg: $0.54
Open: $0.86 52 Wk Low: $0.24



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 59
 Employees 116
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 0

Bioatla Inc
Bioatla Inc is a biotechnology company that focuses on developing antibody-based therapeutics for the treatment of cancer and other diseases. The company utilizes its proprietary Bioaccelerator' platform, which enables the discovery and optimization of therapeutic antibodies with enhanced selectivity and potency. Bioatla's approach combines bioinformatics, protein engineering, and cell biology to create targeted therapies that have the potential to improve patient outcomes. The company's pipeline includes multiple novel antibody candidates in various stages of development, addressing different cancer types and other indications. Bioatla Inc is dedicated to advancing precision medicine through its innovative antibody-based approach to therapy.


   Company Address: 11085 Torreyana Road San Diego 92121 CA
   Company Phone Number: 558-0708   Stock Exchange / Ticker: NASDAQ BCAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADPT   -21.71%    
AMGN   -2.25%    
BIIB        1.98% 
GILD   -2.5%    
IOVA   -1.35%    
MRNA        14.65% 
• View Complete Report
   



Clinical Study

Advancements in Oncology Mecbotamab Vedotin (Mec-V) Shows Promising Survival Rates in Refractory Soft Tissue Sarcomas

Published Fri, Nov 7 2025 4:11 PM UTC

Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Among these, bio-therapeutic innovations such as Mecbotamab Vedotin (Mec-V), an antibody-drug conjugate (ADC) targeting the AXL receptor, have come to the forefro...
Clinical Study

Pioneering Perspectives in Oncology BioAtlas Revolutionary Approach to Solid Tumors

Published Fri, Jul 18 2025 7:12 PM UTC

In the realm of biotechnology and oncology, significant advancements are continually being developed to tackle the complex nature of cancer. BioAtla, Inc., a clinical-stage biotechnology company based in San Diego, stands at the forefront of this innovative frontier. Focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, BioAtla is committed...
Clinical Study

Unraveling the KRAS Conundrum Promising Insights from BioAtlas Mecbotamab Vedotin in Advanced NSCLC Treatment

Published Sun, Dec 29 2024 7:57 PM UTC

In the realm of oncology, few challenges have been as vexing as the treatment of non-small cell lung cancer (NSCLC), particularly in patients harbouring mutations in the KRAS gene. At the recent IASLC 2024 Hot Topic in Basic & Translational Science Meeting, BioAtla Inc. (NASDAQ: BCAB) unveiled compelling data highlighting the clinical outcomes of their investigational drug, ...
Clinical Study

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Ma...

Published Mon, Sep 16 2024 12:01 PM UTC

BioAtla Demonstrates Promising Phase 2 Clinical Trial Results for Ozuriftamab Vedotin in Treating Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck at ESMO 2024BioAtla, a leading innovator in the realm of biopharmaceutical research, has unveiled compelling data from a Phase 2 clinical trial of its pioneering drug, Ozuriftamab Vedotin, at the European Society f...
Stocks on the Move

BioAtla Inc (BCAB) Trailing the Markets Performance

Published Fri, Jul 19 2024 6:57 PM UTC

In recent developments, BioAtla Inc s shares have been trailing the performance of the entire market. This analysis will explore key events surrounding BioAtla Inc (BCAB) to shed light on the potential factors behind this downturn.Event 1 - JMP Securities Raises Price Target for BCAB StockOn July 16, 2024, JMP Securities raised the price target for BioAtla Inc (NASDAQ:BCAB) ...









Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.